Quanticate doubles its footprint in India
New center of excellence to support further development of collaborative, long-term partnerships with leading pharmaceutical companies.
Quanticate, a global data-focused clinical research organisation (CRO), is further expanding its service offering into India with the opening of a new office.
Strategically located in Bangalore, with access to the country’s extensive talent pool in the pharmaceutical services industry, the new office will be a base from which Quanticate will broaden its capabilities for the management, analysis and reporting of data from clinical trials and post-marketing surveillance.
The decision to open the office follows a very successful year for Quanticate, which saw an increase in sales driving the demand for more resources both in India and further afield. The new 16,500-sq. ft. premises doubles the company’s current footprint in the country.
Praveen Dass, VP of clinical data management and head of Indian operations at Quanticate explains: “By expanding our presence in India, we are able to increase our capacity meaning we can cater for more clients on a larger scale.
“We have an ambitious growth strategy to deliver over the next 5 years, which aims to employ over 60 new members of staff in the coming months. Our new office provides the perfect platform for this growth and marks an important milestone in our journey.”
As the company’s new operational center of excellence, the facility will also help Quanticate to provide outstanding customer service for its global client base and support further development of collaborative, long-term partnerships with leading pharmaceutical companies.
The CROs increased presence in the region has recently allowed Quanticate to engage with a diverse range of industry-specific groups, including the Society for Clinical Data Management (SCDM) India and Pharmaceutical Users Software Exchange (PhUSE) India. The company has representatives on the steering committee and co-chaired the first Society for Clinical Data Management (SCDM) Single Day Event (SDE).
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance